Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Nat Immunol. 2010 Aug 1;11(9):846–853. doi: 10.1038/ni.1915

Figure 3.

Figure 3

The suppressive activity of Tr1-like cells induced by AhR activation is mediated by granzyme B. (a) Suppressive activity of human naive CD4+ T cells activated with plate-bound anti-CD3 and soluble anti-CD28, with TCDD, and incubated in contact with responder T cells (Ctrl) or with a Transwell (Transwell). (b) Quantitative real-time PCR analysis of GZMB expression on T cells with or without TCDD, presented relative to GAPDH expression. (c) Flow cytometry of granzyme B expression on T cells with or without TCDD. Numbers in outlined areas (left) indicate percent CD4+ granzyme B–positive (GranB+) cells. (d) Expression of AHR (left) and GZMB (right) in TCDD-treated cells transduced with nonspecific control or AHR-specific siRNA, presented relative to GAPDH expression. (e) Suppressive activity of TCDD-treated T cells left unstimulated or treated with the granzyme B inhibitor AAD-CMK, caspase inhibitors or neutralizing anti-IL-10. (f) GZMB expression (left) and the suppressive activity (right) of TCDD-treated T cells transduced with control siRNA or GNZB-specific siRNA (siGnzB). *P < 0.05 and **P < 0.01, compared with T-Ctrl (b,c), siCtrl (d,f) or no treatment (e; Student’s t-test). Data are representative of two experiments (a,d,f; mean + s.d. of triplicate wells in a and mean + s.d. in d,f), four experiments (b,c; mean + s.d. of duplicates (b) or mean (right, c) or three experiments (e; mean + s.d.).